SELECT ISSUE
HIGHLIGHTS
Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]
Committe on Publication Ethics
A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.
Members Area
Ibrutinib, a Novel Agent in Relapsed or Refractory Chronic Lymphocytic Leukemia
Ana-Maria IVANESCU, Madalina OPREA, Andrei TURBATU, Andrei COLITA and Anca Roxana LUPU
ABSTRACT
Refractory or relapsed chronic lymphocytic leukemia is still a hematologic malignancy with an unfavorable evolution after several lines of chemotherapy, even when associated with immunotherapy.
The additional presence of adverse prognostic factors such as17p deletion, 11 q deletion, unmutated IgVH genes, CD 38 and ZAP 70 expression further limits therapeutic possibilities.
Over the past two years numerous studies have focused on finding new therapeutic options useful in cases of relapsed or refractory chronic lymphocytic leukemia.
Ibrutinib is a new agent that has shown efficacy in treating these cases, the benefits of response and survival rate having been obtained using Ibrutinib as monotherapy, as well as in combination with immunotherapy or chemotherapy